Letter to the Editor

Why Should We Avoid the Use of Rosiglitazone?

Authors: Nasser Mikhail, MD, MSc

Abstract

To the Editor:


The recent release of data regarding the cardiovascular (CV) safety of rosiglitazone (Avandia) raised major public concern. The author presents herein an updated summary of CV safety data of rosiglitazone and provides a rationale for avoiding its use outside the setting of clinical trials.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457–2471.
 
2. GlaxoSmithKline. Study no.ZM2005/00,181/01: Avandia Cardiovascular Event Modeling Project. Available at: http://ctr.gsk.co.uk/Summary/Rosiglitazone/III_CV_modeling.pdf. Accessed July 9, 2007.
 
3. The DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial. Lancet 2007;368:1096–1105.
 
4. Krall RL. Cardiovascular safety of rosiglitazone. Lancet 2007;69:1995–1996.
 
5. Home PD, Pocock SJ, Beck-Nielsen H, et al; for the RECORD Study Group. Rosiglitazone evaluated for cardiac outcomes—an interim analysis. N Engl J Med 2007;357:28–38.
 
6. Dormandy JA, Charbonnel B, Eckland DJA. Secondary prevention of macrovascular events in patients with Type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macrovascular Events): a randomized controlled trial. Lancet 2005; 366:1279–1289.
 
7. McAfee AT, Koro C, Landon J, et al Coronary artery disease outcomes in patients receiving antidiabetic agents. Pharmacoepidemiol Drug Saf 2007;16:711–725.
 
8. Yki-Jarvinen H. Drug therapy: thiazolidinediones. N Engl J Med 2004;351:1106–1118.
 
9. Nissen SE, Wolski K, Topol EJ. Effect of muraglitazar on death and major adverse cardiovascular events in patients with Type 2 diabetes. JAMA 2005;294:2581–2586.
 
10. Goldberg RB, Kendall DM, Deeg MA, et al; for the GLAI Study Investigators. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with Type 2 diabetes. Diabetes Care 2005;28: 1547–1554.